With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.23195-62-2,2-(1H-1,2,4-Triazol-3-yl)pyridine,as a common compound, the synthetic route is as follows.
A BMes2-functionalized phenyl-triazole (3a) ligand (0.10 mmol) and [PtMe2(u-SMe2)]2 (0.032 g, 0.055 mmol) were added to a 20 mL screw-cap vial with of acetone (5 mL). The resulting mixture was heated to and maintained at 75 C for 2 hours. Then, a 0.10 M solution of TsOH in THF (1 mL) was added. The resulting solution was stirred for 1 hour. Next, 0.1 M solution of 2-(1 H-1 ,2,4-triazol-3-yl)pyridine in methanol (2 mL) was added and the mixture was stirred overnight. The solvent was then removed under reduced pressure. The crude product was dissolved in methanol and purified on TLC plate using acetone as the eluent.
23195-62-2, The synthetic route of 23195-62-2 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; QUEEN’S UNIVERSITY AT KINGSTON; WANG, Suning; HUDSON, Zachary, M.; WANG, Xiang; WO2014/138912; (2014); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI